Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

21.780
+0.9804.71%
Volume:3.14M
Turnover:68.10M
Market Cap:22.37B
PE:-16.75
High:21.980
Open:21.160
Low:21.020
Close:20.800
52wk High:38.640
52wk Low:11.360
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:1.08
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.300
ROE:-16.95%
ROA:-5.60%
PB:3.19
PE(LYR):-16.75
PS:7.98

Loading ...

JUNSHI BIO Shares Climb Over 5% as 2025 Net Loss Forecast to Narrow by Approximately 32%

Stock News
·
10 hours ago

Shanghai Junshi Biosciences Forecasts Narrower 2025 Loss Amid Higher Revenue

MT Newswires Live
·
Feb 02

Junshi Bio (01877) Issues Profit Warning, Anticipates 2025 Net Loss Attributable to Owners of Approximately 873 Million Yuan, Representing a 31.85% Year-on-Year Reduction in Losses

Stock News
·
Jan 30

ZhTong A-H Statistics | January 27

Stock News
·
Jan 27

ZhTong Hong Kong Market Analysis | Strait of Hormuz Sparks Market Jitters, Asset Classes Continue to Draw Interest

Stock News
·
Jan 26

Shanghai Junshi Biosciences (1877) Completes 2026 First Tranche Technology Innovation Bonds Issuance

Bulletin Express
·
Jan 26

JUNSHI BIO (01877) Completes Issuance of RMB 1 Billion Sci-Tech Innovation Bond

Stock News
·
Jan 26

Hong Kong Stocks Movement | Select Pharmaceutical Stocks Rally in Afternoon Session: CANSINOBIO (06185) Surges Over 10%, JUNSHI BIO (01877) Gains Over 5%

Stock News
·
Jan 26

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Share Price Is Matching Sentiment Around Its Revenues

Simply Wall St.
·
Jan 25

Shanghai Junshi Biosciences Gets US FDA Approval for Cancer Drug Trial

MT Newswires Live
·
Dec 15, 2025

HK Stock Movement | JUNSHI BIO (01877) Rises Over 4% as FDA Approves JS212 Clinical Trial for Advanced Solid Tumors

Stock News
·
Dec 15, 2025

BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLN

Reuters
·
Dec 10, 2025

Shanghai Junshi Biosciences - Chairman Xiong Jun Intended to Increase Shareholding in a Shares and H Shares for No Less Than RMB100 Mln

THOMSON REUTERS
·
Dec 10, 2025

Junshi Biosciences' Application for Plaque Psoriasis Drug Gets China Approval

MT Newswires Live
·
Dec 08, 2025

Junshi Biosciences' Four Drugs Placed on China's Insurance Drug List

MT Newswires Live
·
Dec 08, 2025

HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List

Stock News
·
Dec 08, 2025

Shanghai Junshi Biosciences (SEHK:1877): Reassessing Valuation After a Sharp Pullback and Strong Year-to-Date Rally

Simply Wall St.
·
Dec 08, 2025

BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug Application

Reuters
·
Dec 05, 2025

Shanghai Junshi Biosciences - Acceptance of New Drug Application for Roconkibart Injection by Nmpa

THOMSON REUTERS
·
Dec 05, 2025

Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted

Stock News
·
Dec 05, 2025